A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Clinical Cancer Genetics Bookmark and Share

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 

Clinical Cancer Genetics

Clinical Cancer Genetics

 
 
 Mission Statement:
 The City of Hope Division of
 Clinical Cancer Genetics is
 committed to being a national
 leader in the advancement
 of cancer genetics, screening
 and prevention, through
 innovative patient care,
 research and education.
 
 
In light of a growing body of research confirming that many common cancers, including breast, ovarian, and colorectal cancer, are hereditary, the Division of Clinical Cancer Genetics (CCG) Cancer Screening & Prevention Program helps people understand their personal cancer risk profiles, offering a comprehensive cancer risk assessment that takes into account family history and genetics, along with environmental and lifestyle factors. With this information, people can take proactive steps to “outsmart cancer.”
 
 
 
 
The division’s Cancer Genetics Education Program (CGEP) offers courses and professional development tools designed to further health care professionals’ understanding of cancer genetics.
 
 

Major initiatives include:

The Intensive Course (IC) promotes community-based, practitioner-level competence in the selection, application and interpretation of genetic testing in order to provide these critical services in underserved areas.
 
 
 
The Clinical Cancer Genetics Community of Practice (CCGCoP) is a network of clinicians who have graduated from the IC and/or the Cancer Genetics Career Development Program (CGCDP), along with members of the CCGCRN. Those who are part of this unique community have access to collaborators and professional support from other community members, and to enhanced continuing professional development activities offered by CCG.
 
 
 
In the Cancer Genetics Career Development Program, outstanding post-graduate research scientists receive training with a focus on cutting edge genetic and genomic technology. Graduates of this program continue their work in cancer genetics with the goal of reducing the burden of cancer among those at highest risk.
 
 
 
Clinical cancer genetics research at City of Hope investigates multiple approaches that utilize the latest findings in cancer genetics in order to improve the prevention, treatment, and support of those with hereditary cancers.
 
 
 
Major initiatives include:
 
The CCG molecular genetics research laboratory uses a multitude of research tests such as MLPA, long range PCR and next generation sequencing as well as a variety of state of the art equipment to prescreen high risk patients for mutations in cancer predisposition genes such as BRCA1, BRCA2 and RAD51. Specific equipment available in the laboratory include:  -Sequenom MassArray Analyzer (MALDI-TOF Mass spectrometry) -Sequenom MassArray Robotic Nanodispenser -Ion Torrent Personal Genome Machine -Ion One Touch -Nanodrop 2000c spectrophotometer -Qubit 2.0 Fluorometer -ABI 3130xl Genetic Analyzer -Veriti 96 well thermocyclers -Gene Amp 9700 PCR systems
 
 
 
 
An essential but often unmet aspect of providing quality care to persons affected by cancer or those at hereditary cancer risk is addressing their psychosocial needs. As such, understanding and minimizing the negative impact of hereditary cancer risk on persons' lives is the focus of the CCG Clinical and Behavioral Research program. The program studies health-related behaviors, quality of life (including emotional, psychological and basic daily living needs), and ethical, legal, and social issues, by going directly to the source--our patients and their family members.
 
 
 
 
An integral component of the research program is the Cancer Genetics Community Research Network (CCGCRN), a prospective research registry protocol initiated at City of Hope as a biospecimen repository with associated personal and family medical history, and psychosocial and clinical follow-up data collection. Collaborating community-based oncogenetic practice sites across the U.S. and Latin America are recruiting thousands of genetic cancer risk assessment patients annually.
 
 
 
 
 
In addition, CGEP staff participate in educational outreach to medical groups, hospital medical staffs and other community health care professionals. The program is supported in part by the National Cancer Institute and the California Research Program.
 
Clinical Cancer Genetics
The City of Hope Division of Clinical Cancer Genetics is committed to being a national leader in the advancement of cancer genetics, screening and prevention, through innovative patient care, research and education.

Contact Us
  • 800-826-HOPE (4673)
  • For more information about the Cancer Screening & Prevention Program, call 626-256-8662, ext. 2.
Beckman Research Institute of City of Hope is internationally  recognized for its innovative biomedical research.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
City of Hope Breakthroughs
Get the latest in City of Hope's research, treatment and news you can use on our blog, Breakthroughs.
 
 


NEWS & UPDATES
  • “Lucky” is not usually a term used to describe someone diagnosed with cancer.  But that’s how 34-year-old Alex Camargo’s doctor described him when he was diagnosed with thyroid cancer — the disease is one of the most treatable cancers at all stages. That doctor was ultimately proved righ...
  • Geoff Berman, 61, starts his day with the motto: “The sun is up. I’m vertical. It’s a good day.” Ever since he’s been in remission from lymphoma, Berman makes a special point of being grateful for each day, reminding himself that being alive is a gift. “I just enjoy living,” he said. “I give e...
  • Neural stem cells have a natural ability to seek out cancer cells in the brain. Recent research from the laboratories of Michael Barish, Ph.D., and Karen Aboody, M.D., may offer a new explanation for this attraction between stem cells and tumors. Prior to joining City of Hope, Aboody, now a professor in the Dep...
  • The American Society of Clinical Oncology, a group that includes more than 40,000 cancer specialists around the country, recently issued a list of the five most profound cancer advances over the past five decades. Near the top of the list was the introduction of chemotherapy for testicular cancer. To many in th...
  • “The dying, as a group, have been horribly underserved.” So says Bonnie Freeman, R.N., D.N.P., A.N.P.-B.C., A.C.H.P.N., a nurse practitioner in the Department of Supportive Care Medicine at City of Hope. After nearly 25 years, primarily in critical care nursing, Freeman saw that the needs of the dying were ofte...
  • “Are we the only ones who feel this way?” Courtney Bitz, L.C.S.W., a social worker in the Sheri & Les Biller Patient and Family Resource Center at City of Hope, often hears this question from couples trying to cope with a breast cancer diagnosis and still keep their relationship strong. The ques...
  • Diabetes investigators at City of Hope are studying the full trajectory of diabetes and metabolic disorders, as well as complications of the disease. One especially promising approach focuses on proteins known as growth factors. Led by Fouad Kandeel, M.D., Ph.D., chair and professor of the Department of Clinica...
  • Acute myeloid leukemia is the most common form of acute leukemia among adults, accounting for 18,000 diagnoses in 2014. Two decades ago, in 1996, the National Comprehensive Cancer Network (NCCN) published its first guidelines for treatment of acute myeloid leukemia, or AML. Margaret O’Donnell, M.D., assoc...
  • Children diagnosed with cancer are more likely than ever before to survive the disease, but with a potential new set of health problems caused by the cancer treatment itself. Those problems can particularly affect the heart, and as doctors and other health care workers try to assess how best to care for this sp...
  • Karen Reckamp, M.D., M.S., has an office next to my own, and we often see patients at the same time. As such, I’ve gotten to know her quite well over the years, and I’ve also gotten a glimpse of many of her patients. She specializes in lung cancer, and most of her patients have tumors […]
  • Today is National Doctors Day, the official day to recognize, thank and celebrate the tremendous work physicians do each and every day. Launched in 1991 via a presidential proclamation from then-President George Bush, the observance offers a chance to reflect on the qualities that define truly great medical car...
  • When considering cancer risk, categories like “women’s cancers” and “men’s cancers” may not matter. A complete medical history, especially of first-degree relatives, must be considered when evaluating risk. A new study drives home that fact. Published in the journal Cancer, the study found a link between a fami...
  • Precision medicine holds promise – on that doctors, especially cancer specialists, can agree. But this sophisticated approach to treatment, which incorporates knowledge about a person’s genetic profile, environment and lifestyle, isn’t yet standard for all cancers. It can’t be. Researchers and scientists are st...
  • Frank Di Bella, 70, is on a mission: Find a cure for metastatic bladder cancer. It’s just possible he might. Although Di Bella isn’t a world-renowned physician, cancer researcher or scientist, he knows how to make things happen. For more than 20 years, he served as chairman of annual fundraising gal...
  • The physical side effects of cancer can damage anyone’s self-confidence, but especially that of women who, rightly or wrongly, are more likely to find their appearance (or their own perception of their appearance) directly connected to their ability to face the world with something resembling aplomb. Furt...